Circulating tumor cells can be shed into the bloodstream by tumors, the company said, and are a key biomarker when it comes to determining the appropriate treatment for patients
Biocept Inc (NASDAQ:BIOC) announced Thursday that it has been awarded a patent in Japan covering its devices for detecting circulating tumor cells (CTCs) and other targets of interest found in the bloodstream.
The claims covered by this patent broadly include the use of binding entities for the capture and detection of any target on any solid surface. It also covers combinations of antibodies for capturing a wide variety of different tumor types.
This patent combines with Biocept’s patented microchannel and cell staining platforms to enable the capture of any cell of interest, including very rare cells, that may be present in blood and any other biological sample type.
“The granting of this Japanese patent broadly expands Biocept’s intellectual property estate for capturing and detecting cells of interest,” CEO Michael Nall said in a statement. “The patent also interfaces very well with our other patented technologies that include our blood collection tube as well as our Target Selector circulating DNA analysis platforms used for guiding patient treatment decisions. We believe the broad coverage of this patent also provides Biocept with the opportunity for potentially out-licensing the technology to other companies with a focus on any target of interest, including single cell analysis and other methodologies.”
Circulating tumor cells can be shed into the bloodstream by tumors, the company said, and are a key biomarker when it comes to determining the appropriate treatment for patients.